Clinical TrialJun 2, 2026, 07:07 AM
Can-Fite Reports Positive Clinical Observations in Pancreatic Cancer Study
AI Summary
Can-Fite BioPharma Ltd. announced positive clinical observations from its ongoing Phase 2a study of namodenoson as a monotherapy for pancreatic cancer. The company highlighted namodenoson's differentiated mechanism of action, including the inhibition of the RAS signaling pathway, which is crucial in pancreatic ductal adenocarcinoma. Enrollment for the study is complete, with several patients demonstrating prolonged disease control, including one patient on therapy for approximately 16 months.
Key Highlights
- Can-Fite reported positive clinical observations in its Phase 2a pancreatic cancer study for namodenoson.
- Namodenoson inhibits the RAS signaling pathway, a key driver in pancreatic cancer.
- One patient has remained on therapy and follow-up for approximately 16 months, showing prolonged disease control.
- Namodenoson's mechanism involves deregulation of RAS, Wnt/β-catenin, and NF-κB signaling pathways.
- Enrollment for the Phase 2a pancreatic cancer study has been completed.
- Namodenoson has Orphan Drug Designation from the U.S. FDA for pancreatic cancer.
Price Impact
More from CANF